Table 1.
Epigenetic modulators.
| Drug | Target | Indication | Status |
|---|---|---|---|
| Romedepsin | HDAC (Zn-dependent HDACs) (inhibitor) | Cutaneous T cell lymphoma | Approved (2004) |
| Vorinostat | Nonselective HDAC (inhibitor) | Cutaneous T cell lymphoma | Approved (2006) |
| Givinostat | HDAC (Class I, II) (inhibitor) | Systemic juvenile idiopathic arthritis, polycythaemia vera | Approved (2010) Orphan drug status |
| Duchenne's muscular dystrophy, Beckers muscular dystrophy | Approved (2013) Orphan drug status |
||
| Relapsed leukaemias and lymphomas | Phase II trials | ||
| Resminostat | Nonselective HDAC (inhibitor) | Hepatocellular carcinoma | Approved (2011) |
| Belinostat | Nonselective HDAC (inhibitor) | Approved (2014) | |
| Pracinostat | HDAC Class I, II, IV | AML, T-cell lymphoma | Approved (2014) Orphan drug status |
| Panobinostat | Nonselective HDAC (inhibitor) | Multiple myeloma | Approved (2015) |
| Tazemetostat | HMT EZH2 (inhibitor) | Advanced epithelioid carcinoma | Approved (2020) |
HDAC, histone deacetylase; HMT, histone methyl transferase.